Anne Wojcicki Reclaims 23andMe with $305M Nonprofit Buyout

Anne Wojcicki is making a decisive return to 23andMe, the genetic testing firm she co-founded, through a $305 million acquisition bid by her nonprofit, TTAM Research Institute. The MOVE outpaces a competing $256 million offer from Regeneron, with a bankruptcy court expected to finalize the decision by June 17. If approved, the deal will transition 23andMe''s core business lines—including its Personal Genome Service and telehealth arm—into nonprofit stewardship, emphasizing consumer empowerment and long-term research.

Investor Optimism has already buoyed MEHCQ stock, which trades over-the-counter, surging 69% year-to-date. The shift to a nonprofit model signals a strategic pivot away from commercial pressures, though the company remains under Chapter 11 proceedings. Wojcicki''s bid underscores a broader trend of mission-driven acquisitions reshaping biotech narratives.